The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
The role of PARP in DNA repair and its therapeutic exploitation
Open accessAbstract
Historically, PARP inhibitors (PARPi) were developed to potentiate the cytotoxic effect of certain chemotherapeutic agents and are currently being investigated in combination with chemotherapy in diverse cancer types. These agents are also radiosensitisers and clinical trials of PARPi with concurrent radiation are required. It has long been recognised that defective DNA repair pathways lead to tumour susceptibility. Recent studies indicate that tumour cells with defective homologous recombination (HR) repair pathways, the classic example being BRCA mutations, are exquisitely sensitive to PARPi. Defects in HR are not restricted to BRCA-associated tumours and other cancer types may be enriched for HR defects and hence susceptible to PARP inhibition. The identification of predictive markers for sensitivity to PARP inhibition is a priority area for research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citationGenome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., et al. (1994) · Nature · doi:10.1038/368258a0 · Cited by 2,052
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
MISMATCH REPAIR IN REPLICATION FIDELITY, GENETIC RECOMBINATION, AND CANCER BIOLOGY
Modrich, P., & Lahue, R. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.000533 · Cited by 1,526
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 820
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Poly(ADP-ribose) polymerase: a molecular nick-sensor
de Murcia, G., & de Murcia, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90280-1 · Cited by 797
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Wang, Z. Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., Schweiger, M., & Wagner, E. F. (1995) · Genes & Development · doi:10.1101/gad.9.5.509 · Cited by 774
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J.-C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Murcia, J. M.-D., & de Murcia, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 745
Schreiber, V., Amé, J.-C., Dollé, P., Schultz, I., Rinaldi, B., Fraulob, V., Ménissier-de Murcia, J., & de Murcia, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202390200 · Cited by 705
El-Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 659
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“Carriers of BRCA1/2 mutations have one functional allele, and can therefore conduct HR repair in normal tissues, but tumour development is dependent on somatic inactivation of the second allele rendering them defective in HR (Welcsh and King, 2001).”
BackgroundSynthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 638
Menissier de Murcia, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 627
PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites
Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J.-Y., Hendzel, M. J., & Poirier, G. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 608
Menear, K. A., Adcock, C., Boulter, R., Cockcroft, X.-L., Copsey, L., Cranston, A., Dillon, K. J., Drzewiecki, J., Garman, S., Gomez, S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001263 · Cited by 584
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Kim, M. Y., Mauro, S., Gévry, N., Lis, J. T., & Kraus, W. L. (2004) · Cell · doi:10.1016/j.cell.2004.11.002 · Cited by 550
Poly(ADP-ribose) Binds to Specific Domains in DNA Damage Checkpoint Proteins
Pleschke, J. M., Kleczkowska, H. E., Strohm, M., & Althaus, F. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006520200 · Cited by 541
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Novel inhibitors of poly(ADP-ribose) synthetase
Purnell, M. R., & Whish, W. J. (1980) · Biochemical Journal · doi:10.1042/bj1850775 · Cited by 527
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Self-citationBenjamin, R. C., & Gill, D. M. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70491-8 · Cited by 487
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase.
Banasik, M., Komura, H., Shimoyama, M., & Ueda, K. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45983-2 · Cited by 476
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Gagné, J.-P., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., & Poirier, G. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn771 · Cited by 414
Veuger, S. J., Curtin, N. J., Richardson, C. J., Smith, G. C. M., & Durkacz, B. W. (2003) · Cancer Research · doi:10.25405/ncl.34607331 · Cited by 392
Self-citationPlummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Self-citationEvolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Ferraris, D. V. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100012m · Cited by 363
On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei
Chambon, P., Weill, J. D., Doly, J., Strosser, M. T., & Mandel, P. (1966) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(66)90502-x · Cited by 344
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P. W. B., Holstege, H., Liu, X., van Drunen, E., Beverloo, H. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4953 · Cited by 335
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
Importance of Poly(ADP-Ribose) Glycohydrolase in the Control of Poly(ADP-Ribose) Metabolism
Davidovic, L., Vodenicharov, M., Affar, E. B., & Poirier, G. G. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5263 · Cited by 326
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Altmeyer, M., Messner, S., Hassa, P. O., Fey, M., & Hottiger, M. O. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp229 · Cited by 325
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Studies on the Polymer of Adenosine Diphosphate Ribose
Nishizuka, Y., Ueda, K., Nakazawa, K., & Hayaishi, O. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95947-8 · Cited by 308
Poly(ADP-ribose) Polymerase Null Mouse Cells Synthesize ADP-ribose Polymers
Shieh, W. M., Amé, J.-C., Wilson, M. V., Wang, Z.-Q., Koh, D. W., Jacobson, M. K., & Jacobson, E. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30069 · Cited by 303
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Thomas, H. D., Calabrese, C. R., Batey, M. A., Canan, S., Hostomsky, Z., Kyle, S., Maegley, K. A., Newell, D. R., Skalitzky, D., Wang, L.-Z., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0552 · Cited by 303
Self-citationPoly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
Schultz, N. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg703 · Cited by 301
Molecular and biochemical features of poly (ADP-ribose) metabolism
Lautier, D., Lagueux, J., Thibodeau, J., M�nard, L., & Poirier, G. G. (1993) · Molecular and Cellular Biochemistry · doi:10.1007/bf01076101 · Cited by 301
A Role of Poly (ADP-Ribose) Polymerase in NF- B Transcriptional Activation
Hassa, P. O., & Hottiger, M. O. (1999) · Biological Chemistry · doi:10.1515/bc.1999.118 · Cited by 296
White, A. W., Almassy, R., Calvert, A. H., Curtin, N. J., Griffin, R. J., Hostomsky, Z., Maegley, K., Newell, D. R., Srinivasan, S., & Golding, B. T. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000950v · Cited by 288
Self-citationQuinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Kennedy, R. D., & D'Andrea, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4171 · Cited by 286
Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers
Jazaeri, A. A., Yee, C. J., Sotiriou, C., Brantley, K. R., Boyd, J., & Liu, E. T. (2002) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282
Boehler, C., Gauthier, L. R., Mortusewicz, O., Biard, D. S., Saliou, J.-M., Bresson, A., Sanglier-Cianferani, S., Smith, S., Schreiber, V., Boussin, F., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016574108 · Cited by 277
Gradwohl, G., Ménissier de Murcia, J. M., Molinete, M., Simonin, F., Koken, M., Hoeijmakers, J. H., & de Murcia, G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.2990 · Cited by 277
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Self-citationDrew, Y., Mulligan, E. A., Vong, W.-T., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomsky, Z., Plummer, E. R., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 261
Self-citationARCON: a novel biology-based approach in radiotherapy
Kaanders, J. H., Bussink, J., & van der Kogel, A. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00929-4 · Cited by 256
Stimulation of the DNA-dependent Protein Kinase by Poly(ADP-Ribose) Polymerase
Ruscetti, T., Lehnert, B. E., Halbrook, J., Le Trong, H., Hoekstra, M. F., Chen, D. J., & Peterson, S. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14461 · Cited by 248
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA
Langelier, M.-F., Planck, J. L., Roy, S., & Pascal, J. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.202507 · Cited by 239
PARP inhibitors for cancer therapy
Curtin, N. J. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940500904x · Cited by 238
Self-citationLiu, L., Markowitz, S. D., & Gerson, S. L. (1996) · PubMed · Cited by 235
Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., & Futscher, B. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.9.1761 · Cited by 229
Mendoza-Alvarez, H., & Alvarez-Gonzalez, R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41568-2 · Cited by 227
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination–Defective Cells
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H. E., Djureinovic, T., Issaeva, N., Sleeth, K., Sharma, R. A., & Helleday, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4716 · Cited by 227
Mechanisms of tolerance to DNA damaging therapeutic drugs
Karran, P. (2001) · Carcinogenesis · doi:10.1093/carcin/22.12.1931 · Cited by 226
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V, & Cutler, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Structure and function of poly(ADP-ribose) polymerase
de Murcia, G., Schreiber, V., Molinete, M., Saulier, B., Poch, O., Masson, M., Niedergang, C., & de Murcia, J. M. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928438 · Cited by 206
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205
Self-citationLangelier, M.-F., Servent, K. M., Rogers, E. E., & Pascal, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708558200 · Cited by 204
Tentori, L., Leonetti, C., Scarsella, M., d’Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V. J., Zupi, G., Zhang, J., et al. (2003) · PubMed · Cited by 204
Ruf, A., de Murcia, G., & Schulz, G. E. (1998) · Biochemistry · doi:10.1021/bi972383s · Cited by 199
Plo, I. (2003) · DNA Repair · doi:10.1016/s1568-7864(03)00116-2 · Cited by 198
Ménissier-de Murcia, J., Molinete, M., Gradwohl, G., Simonin, F., & de Murcia, G. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90302-1 · Cited by 193
Chemopotentiation by PARP inhibitors in cancer therapy
Tentori, L., & Graziani, G. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.010 · Cited by 192
Quinn, J. A., Pluda, J., Dolan, M. E., Delaney, S., Kaplan, R., Rich, J. N., Friedman, A. H., Reardon, D. A., Sampson, J. H., Colvin, O. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.084 · Cited by 189
Pacher, P., Liaudet, L., Bai, P., Virag, L., Mabley, J. G., Haskó, G., & Szabó, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.862 · Cited by 188
Qiao, G.-B., Wu, Y.-L., Yang, X.-N., Zhong, W.-Z., Xie, D., Guan, X.-Y., Fischer, D., Kolberg, H.-C., Kruger, S., & Stuerzbecher, H.-W. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602665 · Cited by 186
Regulation of Poly(ADP-ribose) Polymerase-1 by DNA Structure-specific Binding
Lonskaya, I., Potaman, V. N., Shlyakhtenko, L. S., Oussatcheva, E. A., Lyubchenko, Y. L., & Soldatenkov, V. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413483200 · Cited by 186
Unmasking a killer: DNA O6-methylguanine and the cytotoxicity of methylating agents
Bignami, M., O'Driscoll, M., Aquilina, G., & Karran, P. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00016-8 · Cited by 185
Wu, W. K. K., Wong, H. P. S., Luo, S. W., Chan, K., Huang, F. Y., Hui, M. K. C., Lam, E. K. Y., Shin, V. Y., Ye, Y. N., Yang, Y. H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0205 · Cited by 183
Cherney, B. W., McBride, O. W., Chen, D. F., Alkhatib, H., Bhatia, K., Hensley, P., & Smulson, M. E. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8370 · Cited by 180
Pacher, P., & Szabó, C. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1568 · Cited by 180
A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate Synthase
Chu, E. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.4.460 · Cited by 178
Martin, R. W., Orelli, B. J., Yamazoe, M., Minn, A. J., Takeda, S., & Bishop, D. K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0290 · Cited by 177
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A., Robson, M., Garber, J. E., Domchek, S., Audeh, M. W., Weitzel, J. N., Friedlander, M., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra501 · Cited by 174
Liu, X., Shi, Y., Maag, D. X., Palma, J. P., Patterson, M. J., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Cheng, C. L., Johnson, S. P., Keir, S. T., Quinn, J. A., Ali-Osman, F., Szabo, C., Li, H., Salzman, A. L., Dolan, M. E., Modrich, P., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0128 · Cited by 171
Russo, A. L., Kwon, H.-C., Burgan, W. E., Carter, D., Beam, K., Weizheng, X., Zhang, J., Slusher, B. S., Chakravarti, A., Tofilon, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2079 · Cited by 169
Tao, Z., Gao, P., & Liu, H.-W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906135d · Cited by 166
Epigenetics: poly(ADP‐ribosyl)ation of PARP‐1 regulates genomic methylation patterns
Caiafa, P., Guastafierro, T., & Zampieri, M. (2009) · The FASEB Journal · doi:10.1096/fj.08-123265 · Cited by 165
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M., Kummar, S., Szabo, E., Yancey, M. A., Ji, J., Mannargudi, B., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164
Curtin, N. J., Wang, L.-Z., Yiakouvaki, A., Kyle, S., Arris, C. A., Canan-Koch, S., Webber, S. E., Durkacz, B. W., Calvert, H. A., Hostomsky, Z., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1144-3 · Cited by 164
Self-citationOplustilova, L., Wolanin, K., Mistrik, M., Korinkova, G., Simkova, D., Bouchal, J., Lenobel, R., Bartkova, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 163
Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S., & Gerson, S. L. (1999) · PubMed · Cited by 162
Tong, W., Ohgaki, H., Huang, H., Granier, C., Kleihues, P., & Wang, Z. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63825-4 · Cited by 159
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4016 · Cited by 156
Vilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V. R., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 155
Mukhopadhyay, A., Plummer, E. R., Elattar, A., Soohoo, S., Uzir, B. F., Quinn, J. E., McCluggage, W. G., Maxwell, P., Aneke, H., Curtin, N. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0324 · Cited by 151
Self-citationATP for the DNA Ligation Step in Base Excision Repair Is Generated from Poly(ADP-ribose)
Oei, S. L., & Ziegler, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002429200 · Cited by 147
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
Tentori, L., Portarena, I., & Graziani, G. (2002) · Pharmacological Research · doi:10.1006/phrs.2001.0935 · Cited by 146
Bowman, K. J., Newell, D. R., Calvert, H., & Curtin, N. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1555 · Cited by 144
Self-citationPARP Inhibitor Development for Systemic Cancer Targeting
Zaremba, T., & Curtin, N. J. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668715 · Cited by 144
Self-citationCross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents
Caldecott, K. W., & Jeggo, P. A. (1991) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(91)90046-r · Cited by 143
Bowman, K. J., White, A. W., Golding, B. T., Griffin, R., & Curtin, N. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.670 · Cited by 143
Self-citationABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Palma, J. P., Wang, Y., Rodriguez, L. E., Montgomery, D., Ellis, P. A., Bukofzer, G. T., Niquette, A. L., Liu, X., Shi, Y., Lasko, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1245 · Cited by 142
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Self-citationSmith, L. M., Willmore, E., Austin, C. A., & Curtin, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1224 · Cited by 139
Self-citationHannay, J. A. F., Liu, J., Zhu, Q.-S., Bolshakov, S. V., Li, L., Pisters, P. W. T., Lazar, A. J., Yu, D., Pollock, R. E., & Lev, D. C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0636 · Cited by 138
Chalmers, A. J., Lakshman, M., Chan, N. H. L., & Bristow, R. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.06.001 · Cited by 137
Boulton, S. J., Pemberton, L., Porteous, J. K., Curtin, N. J., Griffin, R., Golding, B. T., & Durkacz, B. W. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.423 · Cited by 136
Self-citationPoly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing
Malanga, M., & Althaus, F. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300437200 · Cited by 135
Horsman, M. R. (1995) · Acta Oncologica · doi:10.3109/02841869509094031 · Cited by 135
Ranson, M., Middleton, M., Bridgewater, J., Lee, S., Dawson, M., Jowle, D., Halbert, G., Waller, S., McGrath, H., Gumbrell, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2198 · Cited by 135
Poly(ADP-ribose)polymerase: a perplexing participant in cellular responses to DNA breakage
Cleaver, J. E., & Morgan, W. F. (1991) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(91)90016-o · Cited by 131
The inhibition of carbohydrate metabolism in ascites-tumour cells by ethyleneimines
Roitt, I. M. (1956) · Biochemical Journal · doi:10.1042/bj0630300 · Cited by 130
The response of Parp knockout mice against DNA damaging agents
Masutani, M., Nozaki, T., Nakamoto, K., Nakagama, H., Suzuki, H. I., Kusuoka, O., Tsutsumi, M., & Sugimura, T. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00033-8 · Cited by 130
Veuger, S. J., Curtin, N. J., Smith, G. C. M., & Durkacz, B. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207984 · Cited by 128
Self-citationFunction of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice
Masutani, M., Nozaki, T., Nishiyama, E., Shimokawa, T., Tachi, Y., Suzuki, H. I., Nakagama, H., Wakabayashi, K., & Sügimura, T. (1999) · Springer eBooks · doi:10.1007/978-1-4419-8740-2_21 · Cited by 127
Audebert, M., Salles, B., Weinfeld, M., & Calsou, P. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.028 · Cited by 127
Griffin, R. J., Srinivasan, S., Bowman, K. J., Calvert, H., Curtin, N. J., Newell, D. R., Pemberton, L., & Golding, B. T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980273t · Cited by 127
Self-citationKhan, O., Gore, M. E., Lorigan, P. C., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A. J., McGown, G., Thorncroft, M. R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.8 · Cited by 123
BRCA1 methylation: a significant role in tumour development?
Catteau, A., & Morris, J. R. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00056-1 · Cited by 122
Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme
Sügimura, T., Fujimura, S., Hasegawa, S., & Kawamura, Y. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90507-2 · Cited by 120
DNA Methylation in Ovarian Cancer
Ahluwalia, A., Hurteau, J. A., Bigsby, R. M., & Nephew, K. P. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6284 · Cited by 118
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Rathi, A., Virmani, A. K., Schorge, J. O., Elias, K. J., Maruyama, R., Minna, J. D., Mok, S. C., Girard, L., Fishman, D. A., & Gazdar, A. F. (2002) · PubMed · Cited by 118
Willers, H., Taghian, A. G., Luo, C., Treszezamsky, A. D., Sgroi, D. C., & Powell, S. N. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0149 · Cited by 117
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers
Powell, C. B., Mikropoulos, C., Kaye, S. B., Nutting, C. M., Bhide, S., Newbold, K. L., & Harrington, K. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.003 · Cited by 113
Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M., & Sebolt, J. S. (1991) · PubMed · Cited by 112
Wang, C.-J., Horiuchi, A., Imai, T., Ohira, S., Itoh, K., Nikaido, T., Katsuyama, Y., & Konishi, I. (2004) · The Journal of Pathology · doi:10.1002/path.1507 · Cited by 112
Boulton, S. J. (1999) · Carcinogenesis · doi:10.1093/carcin/20.2.199 · Cited by 111
PARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 110
Overexpression of RAD51 occurs in aggressive prostatic cancer
Mitra, A., Jameson, C., Barbáchano, Y., Sánchez, L., Kote‐Jarai, Z., Peock, S., Sodha, N., Bancroft, E. K., Fletcher, A., Cooper, C., et al. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03448.x · Cited by 108
Audeh, M. W., Penson, R. T., Friedlander, M. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5500 · Cited by 107
Eustermann, S., Brockmann, C., Mehrotra, P. V., Yang, J., Loakes, D., West, S. C., Ahel, I., & Neuhaus, D. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1747 · Cited by 107
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106
Self-citationPlummer, E. R., Middleton, M. R., Jones, C., Olsen, A. L., Hickson, I. D., McHugh, P. J., Margison, G. P., McGown, G., Thorncroft, M. R., Watson, A. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2353 · Cited by 103
Self-citationGelmon, K. A., Hirte, H. W., Robidoux, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3002 · Cited by 103
Koyanagi, K., Mori, T., O'Day, S. J., Martinez, S. R., Wang, H.-J., & Hoon, D. S. �. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4198 · Cited by 100
Tentori, L., Leonetti, C., Scarsella, M., Muzi, A., Mazzon, E., Vergati, M., Forini, O., Lapidus, R. G., Xu, W., Dorio, A. S., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5916fje · Cited by 100
Plummer, R., Lorigan, P. C., Evans, J., Steven, N. M., Middleton, M. R., Wilson, R., Snow, K., Dewji, R., & Calvert, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8013 · Cited by 98
Asakawa, H., Koizumi, H., Koike, A., Takahashi, M., Wu, W., Iwase, H., Fukuda, M., & Ohta, T. (2010) · Breast Cancer Research · doi:10.1186/bcr2486 · Cited by 98
Rácz, I., Tory, K., Gallyas, F., Berente, Z., Ősz, E., Jaszlits, L., Bernath, S., Sümegi, B., Rabloczky, G., & Literati-Nagy, P. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00935-2 · Cited by 97
Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro
Wedge, S. R., Porteous, J. K., May, B., & Newlands, E. S. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.85 · Cited by 95
Loh, V. M. J., Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Eversley, P. J., Gomez, S., Hoare, J., Kerrigan, F., Matthews, I. T. W., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.026 · Cited by 94
Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Kerrigan, F., Loh, V. M. J., Martin, N. M. B., Menear, K. A., & Smith, G. C. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.10.081 · Cited by 90
Drew, Y., & Plummer, R. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.10.001 · Cited by 88
Morrow, D. A., Brickman, C. M., Murphy, S. A., Baran, K. W., Krakover, R., Dauerman, H. L., Kumar, S., Slomowitz, N., Grip, L. T., McCabe, C. H., et al. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0230-1 · Cited by 88
Daniel, R. A., Rozanska, A. L., Thomas, H. D., Mulligan, E. A., Drew, Y., Castelbuono, D. J., Hostomský, Z., Plummer, E. R., Boddy, A. V., Tweddle, D. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1095 · Cited by 86
Self-citationHow to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation
Mangerich, A., & Bürkle, A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25683 · Cited by 85
Horton, T. M., Jenkins, G. N., Pati, D., Zhang, L., Dolan, M. E., Ribes‐Zamora, A., Bertuch, A. A., Blaney, S. M., Delaney, S. L., Hegde, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0142 · Cited by 85
Yap, T. A., Walton, M. I., Hunter, L.-J. K., Valenti, M. R., Brandon, A. D. H., Eve, P. D., Ruddle, R. R., Heaton, S. P., Henley, A. T., Pickard, L., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0760 · Cited by 84
Gaymes, T. J., Shall, S., MacPherson, L. J., Twine, N. A., Lea, N. C., Farzaneh, F., & Mufti, G. J. (2009) · Haematologica · doi:10.3324/haematol.2008.001933 · Cited by 83
Wang, H., Cheng, K.-C., Lin, C., Hsu, S., Fang, W., Hsu, T.-F., Chiu, C., Chang, H., Hsu, C., & Lee, A. Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01701.x · Cited by 82
Liu, X., Shi, Y., Guan, R., Donawho, C. K., Luo, Y., Palma, J. P., Zhu, G., Johnson, E. F., Rodriguez, L. E., Ghoreishi-Haack, N. S., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0240 · Cited by 81
Ohashi, A., Zdzienicka, M. Z., Chen, J., & Couch, F. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414669200 · Cited by 80
Pacher, P., Liaudet, L., Mabley, J. G., Cziráki, A., Haskó, G., & Szabó, C. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.2.369 · Cited by 79
Calabrese, C. R., Batey, M. A., Thomas, H. D., Durkacz, B. W., Wang, L.-Z., Kyle, S., Skalitzky, D. J., Li, J., Zhang, C. R., Boritzki, T. J., et al. (2003) · PubMed · doi:10.25405/ncl.34611858 · Cited by 78
Self-citationHead and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427
Khan, K., Araki, K., Wang, D., Li, G., Li, X., Zhang, J., Xu, W., Hoover, R. K., Lauter, S., O'Malley, B., et al. (2009) · Head & Neck · doi:10.1002/hed.21195 · Cited by 77
Wang, Z., Li, M., Lu, S., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.3.2380 · Cited by 74
Intact Mre11/Rad50/Nbs1 Complex Predicts Good Response to Radiotherapy in Early Breast Cancer
Söderlund, K., Stål, O., Skoog, L. K., Rutqvist, L. E., Nordenskjöld, B. A., & Stenmark‐Askmalm, M. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.12.005 · Cited by 73
Zaremba, T., Thomas, H. D., Cole, M. F., Coulthard, S. A., Plummer, E. R., & Curtin, N. J. (2011) · Biochemical Journal · doi:10.1042/bj20101723 · Cited by 72
Self-citationRecognition of Platinum−DNA Damage by Poly(ADP-ribose) Polymerase-1
Zhu, G., Chang, P., & Lippard, S. J. (2010) · Biochemistry · doi:10.1021/bi100775t · Cited by 71
Press, J. Z., Kenyon, J. A., Xue, H., Miller, M. A., Luca, A. D., Miller, D. M., Huntsman, D. D., Gilks, C. B., McAlpine, J. N., & Wang, Y. Z. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.03.011 · Cited by 70
Single-Molecule Behavior of Monomeric and Heteromeric Kinesins
Pierce, D. W., Hom-Booher, N., Otsuka, A. J., & Vale, R. D. (1999) · Biochemistry · doi:10.1021/bi9830009 · Cited by 69
Barendsen, G. W., Chris van, B. R. E. E., & Franken, N. A. P. (2001) · International Journal of Oncology · doi:10.3892/ijo.19.2.247 · Cited by 68
Bedikian, A. Y., Papadopoulos, N. E., Kim, K. B., Hwu, W., Homsi, J., Glass, M. R., Cain, S., Rudewicz, P. J., Vernillet, L., & Hwu, P. (2009) · Cancer Investigation · doi:10.1080/07357900802709159 · Cited by 67
Jacob, D., Bahra, M., Langrehr, J. M., Boas‐Knoop, S., Stefaniak, R., Davis, J., Schumacher, G., Lippert, S., & Neumann, U. P. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04496.x · Cited by 66
PARP1 deficiency exacerbates diet-induced obesity in mice
Devalaraja-Narashimha, K. B., & Padanilam, B. J. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0402 · Cited by 65
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide
Mendeleyev, J., Kirsten, E., Hakam, A., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00189-7 · Cited by 64
Ben‐Hur, E., Chen, C., & Elkind, M. M. (1985) · PubMed · Cited by 64
Szenczi, O., Kemecsei, P., Holthuijsen, M. F. J., van Riel, N. A. W., Vusse, G. J., Pacher, P., Szabó, C., Kollai, M., Ligeti, L., & Ivanics, T. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.023 · Cited by 63
Gallmeier, E., & Kern, S. E. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1909 · Cited by 62
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Y., & Calvert, H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1414.020 · Cited by 61
Gajewski, T. F., Sosman, J. A., Gerson, S. L., Liu, L., Dolan, M. E., Lin, S., & Vokes, E. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0060 · Cited by 61
Kopetz, S., Mita, M. M., Mok, I., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3577 · Cited by 61
Cited by
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
DNA repair targeted therapy: The past or future of cancer treatment?
Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., & Turchi, J. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.003 · Cited by 387
Oxidatively induced DNA damage and its repair in cancer
Dizdaroglu, M. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.002 · Cited by 254
Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers
Buckley, A. M., Lynam-Lennon, N., O’Neill, H., & O’Sullivan, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0247-2 · Cited by 254
Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes
Cantó, C., Sauve, A. A., & Bai, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.004 · Cited by 246
Metadata
- Authors
- Javle, M., & Curtin, N. J.
- Venue
- British Journal of Cancer
- Published
- 2011-10
- Volume
- 105
- Issue
- 8
- Pages
- 1114-1122
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2124092811
- Cited by
- 320
- References
- 220
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.